How Far beyond Diabetes Can the Benefits of Glucagon-like Peptide-1 Receptor Agonists Go? A Review of the Evidence on Their Effects on Hepatocellular Carcinoma
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
How Far beyond Diabetes Can the Benefits of Glucagon-like Peptide-1 Receptor Agonists Go? A Review of the Evidence on Their Effects on Hepatocellular Carcinoma
Authors
Keywords
-
Journal
Cancers
Volume 14, Issue 19, Pages 4651
Publisher
MDPI AG
Online
2022-09-26
DOI
10.3390/cancers14194651
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Exendin-4 alleviates steatosis in an in vitro cell model by lowering FABP1 and FOXA1 expression via the Wnt/-catenin signaling pathway
- (2022) Olfa Khalifa et al. Scientific Reports
- Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease
- (2022) Stergios A. Polyzos et al. Current Obesity Reports
- Clinical and Genetic Predictors of Glycemic Control and Weight Loss Response to Liraglutide in Patients with Type 2 Diabetes
- (2022) Artemis Kyriakidou et al. Journal of Personalized Medicine
- Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care
- (2022) Elpiniki Rentzeperi et al. Journal of Personalized Medicine
- Glucagon‐like peptide ‐1, glucose‐dependent insulinotropic polypeptide, and glucagon receptor poly‐agonists: a new era in obesity pharmacotherapy
- (2022) Is‐haq O. Malik et al. Obesity
- The effects of sodium-glucose cotransporter 2 inhibitors on hepatocellular carcinoma: From molecular mechanisms to potential clinical implications
- (2022) Konstantinos Arvanitakis et al. PHARMACOLOGICAL RESEARCH
- Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease
- (2022) Naoto Fujiwara et al. Science Translational Medicine
- Management of non-alcoholic fatty liver disease
- (2021) Maria Letizia Petroni et al. BMJ-British Medical Journal
- Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
- (2021) Alessandro Mantovani et al. Metabolites
- Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis
- (2021) Yuzhao Dai et al. Frontiers in Endocrinology
- GLP-1 reduces the migration of hepatocellular carcinoma cells via suppression of the stress-activated protein kinase/c-Jun N-terminal kinase pathway
- (2021) Noriko Yamada et al. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- Type 2 diabetes and cancer: an umbrella review of observational and Mendelian randomisation studies
- (2021) Jonathan Pearson-Stuttard et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- NASH limits anti-tumour surveillance in immunotherapy-treated HCC
- (2021) Dominik Pfister et al. NATURE
- GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs
- (2021) Dario Giugliano et al. Cardiovascular Diabetology
- Glucose-Like Peptide-1 Receptor Agonists and Hepatic Decompensation Events in Patients With Cirrhosis and Diabetes
- (2021) Tracey G. Simon et al. Clinical Gastroenterology and Hepatology
- The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD
- (2021) Chandani Patel Chavez et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States
- (2021) Donghee Kim et al. JOURNAL OF HEPATOLOGY
- Comprehensive analysis of LncRNAs expression profiles in an in vitro model of steatosis treated with Exendin-4
- (2021) Khaoula Errafii et al. Journal of Translational Medicine
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
- (2021) Juan P. Frías et al. NEW ENGLAND JOURNAL OF MEDICINE
- GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
- (2021) Xin Zhao et al. Frontiers in Endocrinology
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
- (2021) DIABETES CARE
- Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy
- (2021) Angeliki M Angelidi et al. ENDOCRINE REVIEWS
- Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice
- (2021) Sean Wharton et al. POSTGRADUATE MEDICINE
- GLP-1 Receptor Agonist Effects on Lipid and Liver Profiles in Patients with Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis
- (2021) Shahla Rezaei et al. Canadian Journal of Gastroenterology and Hepatology
- Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
- (2021) Yuan Zhu et al. Frontiers in Endocrinology
- Design of a highly potent GLP-1R and GCGR dual-agonist for recovering hepatic fibrosis
- (2021) Nazi Song et al. Acta Pharmaceutica Sinica B
- Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials
- (2020) Fabio Marsico et al. EUROPEAN HEART JOURNAL
- MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease
- (2020) Mohammed Eslam et al. GASTROENTEROLOGY
- Exendin‐4 enhances the sensitivity of prostate cancer to enzalutamide by targeting Akt activation
- (2020) He Wenjing et al. PROSTATE
- Role of ATP-binding cassette transporter A1 in suppressing lipid accumulation by glucagon-like peptide-1 agonist in hepatocytes
- (2020) Jingya Lyu et al. Molecular Metabolism
- Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States
- (2020) Zobair M. Younossi et al. Clinical Gastroenterology and Hepatology
- Synergistic anti-tumor effects of Liraglutide, a glucagon-like peptide-1 receptor agonist, along with Docetaxel on LNCaP prostate cancer cell line
- (2020) Samane Eftekhari et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Glucagon-Like Peptide-1 Receptor Agonist Prevented the Progression of Hepatocellular Carcinoma in a Mouse Model of Nonalcoholic Steatohepatitis
- (2020) Motoyasu Kojima et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Glucagon-like peptide-1 analogues and thyroid cancer: An analysis of cases reported in the European pharmacovigilance database
- (2020) Ghanshyam Mali et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Pharmacogenetics of the Glucagon-like Peptide-1 Receptor Agonist Liraglutide: A Step Towards Personalized Type 2 Diabetes Management
- (2020) Artemis Kyriakidou et al. CURRENT PHARMACEUTICAL DESIGN
- Liraglutide activates nature killer cell-mediated antitumor responses by inhibiting IL-6/STAT3 signaling in hepatocellular carcinoma
- (2020) Xian Lu et al. Translational Oncology
- Liraglutide Alleviates Hepatic Steatosis by Activating the TFEB-Regulated Autophagy-Lysosomal Pathway
- (2020) Yunyun Fang et al. Frontiers in Cell and Developmental Biology
- Hepatokines and adipokines in NASH-related hepatocellular carcinoma
- (2020) Ozlem Kucukoglu et al. JOURNAL OF HEPATOLOGY
- Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson’s Disease
- (2019) Liping Zhang et al. Journal of Parkinsons Disease
- From NASH to HCC: current concepts and future challenges
- (2019) Quentin M. Anstee et al. Nature Reviews Gastroenterology & Hepatology
- Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis
- (2019) Srilaxmi Kalavalapalli et al. JOURNAL OF ENDOCRINOLOGY
- The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis
- (2019) Zobair M. Younossi et al. JOURNAL OF HEPATOLOGY
- Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
- (2019) Richard Pratley et al. LANCET
- New Insights into Beta-Cell GLP-1 Receptor and cAMP Signaling
- (2019) Alejandra Tomas et al. JOURNAL OF MOLECULAR BIOLOGY
- Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases
- (2019) Maddalena Grieco et al. Frontiers in Neuroscience
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2019) Søren L Kristensen et al. Lancet Diabetes & Endocrinology
- Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy
- (2019) Xinyang Yu et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Liraglutide Decreases Hepatic Inflammation and Injury in Advanced Lean Non-Alcoholic Steatohepatitis
- (2018) David H Ipsen et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- Expression of the glucagon-like peptide-1 receptor and its role in regulating autophagy in endometrial cancer
- (2018) Ranka Kanda et al. BMC CANCER
- GLP-1 treatment protects endothelial cells from oxidative stress-induced autophagy and endothelial dysfunction
- (2018) Xiangsheng Cai et al. International Journal of Biological Sciences
- Exendin-4, a Glucagonlike Peptide-1 Receptor Agonist, Attenuates Breast Cancer Growth by Inhibiting NF-κB Activation
- (2017) Chikayo Iwaya et al. ENDOCRINOLOGY
- Liraglutide, a glucagon-like peptide-1 analog, induce autophagy and senescence in HepG2 cells
- (2017) Gabriele Catyana Krause et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Inhibition of exendin-4-induced steatosis by protein kinase A in cultured HepG2 human hepatoma cells
- (2017) Alice Y. Chen-Liaw et al. IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL
- Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
- (2017) Zobair Younossi et al. Nature Reviews Gastroenterology & Hepatology
- The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP–PKA–EGFR–STAT3 axis
- (2017) M Zhou et al. ONCOGENE
- Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis
- (2017) Yajie Dong et al. Clinics and Research in Hepatology and Gastroenterology
- Use of incretin agents and risk of pancreatic cancer: a population-based cohort study
- (2016) L. M. Knapen et al. DIABETES OBESITY & METABOLISM
- Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials
- (2016) Karolin Bettge et al. DIABETES OBESITY & METABOLISM
- Type 2 Diabetes Mellitus and Cancer: The Role of Pharmacotherapy
- (2016) Gadi Shlomai et al. JOURNAL OF CLINICAL ONCOLOGY
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies
- (2015) K. K. Tsilidis et al. BMJ-British Medical Journal
- Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies
- (2015) K. K. Tsilidis et al. BMJ-British Medical Journal
- Exenatide can inhibit calcification of human VSMCs through the NF-kappaB/RANKL signaling pathway
- (2014) Jun-Kun Zhan et al. Cardiovascular Diabetology
- Exendin-4, a GLP-1 Receptor Agonist, Attenuates Prostate Cancer Growth
- (2014) Takashi Nomiyama et al. DIABETES
- Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J)
- (2014) Yuichiro Eguchi et al. HEPATOLOGY RESEARCH
- Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance
- (2012) Karthika Natarajan et al. BIOCHEMICAL PHARMACOLOGY
- Impaired Regulation of the Incretin Effect in Patients with Type 2 Diabetes
- (2011) Jonatan I. Bagger et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Glucagon Like Peptide-1 Receptor Expression in the Human Thyroid Gland
- (2011) Belinda Gier et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis
- (2011) Gianluca Svegliati-Baroni et al. LIVER INTERNATIONAL
- Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide
- (2010) Anne Flint et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation
- (2010) Lotte Bjerre Knudsen et al. ENDOCRINOLOGY
- Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway
- (2010) Nitika Arora Gupta et al. HEPATOLOGY
- Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design
- (2008) Naga P. Chalasani et al. Contemporary Clinical Trials
- Comparison of Single and Combined Treatment with Exenatide and Metformin on Menstrual Cyclicity in Overweight Women with Polycystic Ovary Syndrome
- (2008) Karen Elkind-Hirsch et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The incretin system and its role in type 2 diabetes mellitus
- (2008) J HOLST et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now